Semaglutide shown to cut COPD flare‑ups and asthma attacks in study

A study presented at the European Respiratory Society (ERS) Congress in Barcelona indicates that the diabetes and weight‑loss medication semaglutide may cut the frequency of asthma attacks by as much as 40%. The research was led by Chloe Bloom, a clinical associate professor in respiratory epidemiology at the National Heart & Lung Institute, Imperial College London, and the findings were delivered by Dr. Bohee Lee during the conference.

The analysis, which evaluated the impact of semaglutide on respiratory outcomes, suggests a significant protective effect for individuals with asthma, adding to the drug’s established role in managing type 2 diabetes and obesity. While the results are preliminary, they highlight a potential new therapeutic avenue for reducing asthma exacerbations, prompting further investigation into the mechanisms behind the observed benefit and the broader applicability of semaglutide in respiratory care.